Lesiplus

Drospirenone, the active ingredient in Lesiplus, is a combined oral contraceptive presented as a tablet for oral use. Together with ethinylestradiol, it forms a hormonal contraceptive that inhibits ovulation, alters cervical mucus, and induces endometrial changes to prevent pregnancy in women of reproductive age.

GNH USA supplies Lesiplus as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, pharmacies and clinics worldwide, providing reliable access to this EU‑approved medication.

Lesiplus, a combined oral contraceptive, acts on the hormonal regulation pathway to prevent unintended pregnancy. - Prevention of pregnancy: provides reliable hormonal contraception for women of reproductive age. - Menstrual cycle regulation: helps achieve more predictable menstrual bleeding patterns. - Reduction of ovarian cysts: may decrease the formation of functional ovarian cysts.

Lesiplus may cause a range of adverse reactions, most of which are mild and transient.

Common Side Effects: - Nausea: mild to moderate stomach upset. - Headache: tension‑type or migraine‑like pain. - Breast tenderness: soreness or swelling of breast tissue. - Weight gain: modest increase in body weight. - Mood changes: irritability or mood swings. - Spotting: irregular vaginal bleeding between periods.

Serious or Rare Side Effects: - Venous thromboembolism: deep vein thrombosis or pulmonary embolism. - Hypertension: significant increase in blood pressure. - Liver disorders: jaundice or abnormal liver function tests. - Gallbladder disease: formation of gallstones or cholecystitis. - Severe allergic reaction: rash, swelling, or anaphylaxis. - Visual disturbances: sudden vision loss or retinal vein occlusion.

Before prescribing Lesiplus, clinicians should assess individual risk factors and consider contraindications. - Smoking: avoid use in women over 35 who smoke heavily. - Cardiovascular disease: contraindicated in patients with history of stroke, myocardial infarction, or uncontrolled hypertension. - Liver disease: use with caution in patients with active liver disease. - Migraine with aura: avoid in women who experience migraine headaches with visual disturbances. - Pregnancy and lactation: not recommended during pregnancy or while breastfeeding. - Store at ambient temperature: keep below 25 °C, retain in original packaging, protect from moisture and direct sunlight.

Lesiplus can interact with several medications, altering its efficacy or safety profile.

Major Interactions (Avoid): - Antiepileptic drugs (e.g., carbamazepine, phenytoin): may reduce contraceptive effectiveness. - Rifampin and other strong enzyme inducers: significantly decrease hormone levels. - Certain antivirals (e.g., ritonavir): may lower contraceptive efficacy.

Moderate Interactions (Monitor Closely): - Antifungal agents (e.g., fluconazole): may increase hormone concentrations. - St. John’s wort: may modestly reduce contraceptive effect. - Diuretics (e.g., thiazides): may affect fluid balance and blood pressure.